Abbott Laboratories (NYSE:ABT) released first-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below.
This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation.
View the webcast at https://edge.media-server.com/mmc/p/qgffrnte/
Summary
Abbott Laboratories reported Q1 adjusted earnings per share of $1.15, in line with expectations despite earlier financing costs and a weaker respiratory season.
The acquisition of Exact Sciences was completed, anticipated to add $3 billion in sales for 2026, enhancing the company’s diagnostics portfolio.
Medical device pipeline achievements include early launches and trial completions, with future clinical trials set to expand their technological offerings.
Diagnostics sales rose 2%, driven by core lab growth, while rapid and molecular diagnostics saw a 10% decline due to lower respiratory testing demand.
Nutrition sales were slightly above expectations, with strategic pricing actions beginning to show positive volume growth effects.
EPD pharmaceutical sales increased by 9% with broad market growth, while medical devices grew 8.5%, led by cardiovascular devices.
The company expects accelerated growth in the second half of the year, driven by nutrition strategy execution, electrophysiology and core lab diagnostics growth, and the integration of Exact Sciences.
Future guidance includes 6.5% to 7.5% comparable sales growth for 2026, with adjusted earnings per share guidance midpoint revised to $5.48 due to $0.20 dilution from Exact Sciences acquisition.
Full Transcript
OPERATOR
Good morning and thank you for standing by. Welcome to Abbott Laboratories’ first quarter 2026 earnings conference call. All participants will be able to listen only until the question and answer portion of this call. During the question and answer session, you will be able to ask your question by pressing the star 11 keys on your touchtone phone. This call is being recorded by Abbott with the exception of any participants questions asked during the question and answer session. The entire call, including the question and answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott Laboratories’ express written permission. I would now like to introduce Mr. Mike Camilla,, Vice President, Investor Relations
Mike Camilla (Vice President, Investor Relations)
Good morning and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer, and Phil Boudreau, Executive Vice President, Finance and Chief Financial Officer. Robert and Phil will provide opening remarks following their comments. We’ll take your questions before we get started. Some statements made today may be forward looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2026. Abbott cautions that these forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, which Risk Factors to our Annual Report on Form 10K for the year ended December 31, 2025. Abbott undertakes no obligation to release publicly any revisions to forward looking statements as a result of subsequent events or developments except as required by law on today’s conference call. As in the past, non GAAP financial measures will be used to help investors understand Abbott’s ongoing business performance. These non GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at Abbott.com Note that Abbott has not provided the related GAAP financial measures on a forward looking basis for the non GAAP financial measures for which it is providing guidance because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items which could significantly impact Abbott’s results in accordance with gaap. Unless otherwise noted, our commentary on sales growth refers to comparable sales growth which includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Our definition of comparable sales growth can be found on page two of our press release issued earlier today and a reconciliation table that contains data needed to calculate comparable sales growth can be found on page 13. With that, I will now turn the call over to Robert.
Robert Ford (Chairman and Chief Executive Officer)
Thanks Mike. Good morning everyone and thank you for joining us. Our results in the first quarter were aligned with our expectations for the start of the year that included delivering adjusted earnings per share of $1.15 consistent with our guidance. Despite absorbing the impact of earlier than planned financing costs related to our acquisition of Exact Sciences and a weaker than expected respiratory season, this quarter also marked an important strategic milestone for Abbott with the completion of our acquisition of Exact Sciences. This acquisition adds a new high growth business to the Abbott portfolio, further strengthening our leadership position in diagnostics and expanding our presence into one of the fastest growing areas of healthcare cancer diagnostics. As we communicate at the time of the acquisition announcement, we forecast the addition of Exact Sciences to add approximately $3 billion of incremental sales in 2026 and accelerate Abbott’s long term sales growth rate. Before I summarize our first quarter results, I wanted to highlight a few pipeline achievements in our medical device business. An earlier than planned approval and launch of two new PFA catheters, completion of patient enrollment in our Catalyst left atrial Appendage device trial, initiation of development activities to bring an implantable extravascular ICD product to market, and the announcement of positive results from our randomized control trial which demonstrated that people with Type 2 diabetes on basal insulin therapy benefited from using Libre, including seeing reductions in HbA1c and increased time spent in healthy glucose range. In addition to these achievements, our teams are preparing to initiate patient enrollment in several important clinical trials in the second half of this year. These trials represent a unique opportunity that could position Abbott to bring a new wave of highly differentiated technologies to the market. This pipeline of new technologies includes a balloon expandable TAVR valve, a leadless conduction system pacing device that utilizes our revolutionary Aver leadless pacemaker, a mitral replacement valve developed following our acquisition of Cephia Valve Technologies, a peripheral IVL device developed following our acquisition of CSI, and a wearable continuous lactate monitoring sensor that will monitor for sepsis following discharge from hospital. I’ll now summarize our first quarter results before I turn the call over to Phil and I’ll start with diagnostics where sales increased 2% on a comparable basis. In core lab diagnostics, growth of 3% was driven by growth in the US, Europe and Latin America. Sales of core lab diagnostic tests, which exclude capital equipment and digital health solutions, increased on both a year over year and sequential basis and this is a trend that we expect to continue and drive higher growth in the second half of the year compared to the first half. In our rapid and molecular diagnostic business, sales declined 10% reflecting lower demand for respiratory virus testing due to a much weaker respiratory season compared to last year and in cancer diagnostics, sales grew 13% on a comparable basis driven by mid teens growth of cologuard and high teens growth in international markets. Moving to nutrition where sales finished slightly ahead of our expectations for the quarter. As discussed on our January earnings call, results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025 with an objective of re accelerating volume growth. While we are still early in the transition back toward a more sustainable balance between price and volume driven growth, I’m encouraged by the progress we’re making. Early data indicates we are seeing the intended effect with volume growth beginning to follow our pricing actions. We continue to expect that these pricing actions combined with the launch of several new products will result in growth improving over the course of the year. Turning to EPD, our pharmaceutical business where sales increased 9% in the quarter, growth was broad based across the markets we serve which included double digit growth in several countries across Latin America and Asia Pacific regions. Demand in these markets continues to be supported by favorable long term health care economic and demographic trends. With a broad product offering across five therapeutic areas and an expanding biosimilars portfolio which includes several market leading oncology therapies, we are well positioned to serve the growing customer base in these markets and I’ll wrap up with medical devices where sales grew 8.5%. Growth was led by strong performance in our cardiovascular device businesses. This included double digit growth in electrophysiology, heart failure and rhythm management. In electrophysiology growth of 13% included contributions from two pulsed fueled ablation catheter launches in the quarter. The launch of our Volt PFA catheter contributed to a growth of 14% in the US and the launch of our Tactaflex Duo catheter helped drive mid teens growth in Europe. As we broaden the launch of both catheters, we expect growth in our electrophysiology business to accelerate. In rhythm management, sales grew 13% making third consecutive quarter that we have delivered double digit growth and continued our track record of significantly outperforming the market. In heart failure. Growth of 12% was driven by our market leading portfolio of heart assist devices which offer treatment for chronic and temporary conditions in diabetes care, continuous glucose monitoring sales were $2 billion and grew 7.5% growth in the quarter reflects an impact from a delay in the renewal process related to an international tender. We also saw the expected impact from a challenging comparison to last year. This comparison relates to shelf restocking dynamics that occurred in the first half of 2025, a topic that we discussed on an earnings call last year. As we look forward to the second quarter, we expect CGM to return to double digit growth. So in summary, our results in the quarter were in line with our expectations to start the year. We remain confident in our expectation for an acceleration in growth in the second half of the year and we have clear visibility to the key drivers of that acceleration and are highly focused on executing on them. Those drivers include first, executing our growth strategy in nutrition which is underway and on track with our expectations. Second, we see a clear path to accelerating growth in both electrophysiology and core lab diagnostics supported by best in Class portfolios, new product launches and improving market conditions. Third, we will continue our proven track record of delivering strong sustainable performance in EPD and across our medical devices portfolio. And finally, we are successfully integrating Exact Sciences which adds a compelling high growth business to the Abbott portfolio, further strengthening our ability to deliver long term sustainable growth and I’ll turn over the call to Phil.
Phil Boudreau (Executive Vice President, Finance and Chief Financial Officer)
Thanks Robert. As a result of the March 23rd close of our acquisition of Exact Sciences, our first quarter financial results include the results of the Exact Sciences business from the close date through the end of the quarter. As Mike mentioned, our press release issued this morning provides sales growth in the quarter on a comparable basis which includes the full quarter sales of Exact Sciences in both the prior and current year to align with our reporting of comparable sales growth. Our full year 2026 sales growth outlook of 6.5 to 7.5% is now on a comparable basis as well. The sales growth outlook includes the full year sales of Exact Sciences in both the prior and current year compared to our previous full year. Adjusted earnings per share guidance range midpoint of $5.68. Our new guidance range midpoint of $5.48 reflects $0.20 of dilution related to the Exact Sciences acquisition consistent with our assumption at the time of the announced transaction. Turning to our first quarter results, sales increased 3.7% on a comparable basis and adjusted earnings per share of $1.15 grew 6% compared to the prior year. Foreign exchange had a favorable year over year impact of 4% on first quarter sales. Earlier we saw the US dollar weaken which resulted in a favorable impact on sales compared to exchange rates at the time of our earnings Call in January regarding other aspects of the P&L. The adjusted gross margin profile was 56.3% of sales. Adjusted R&D was 6.7% of sales and adjusted SGA was 29.3% of sales. Based on current rates, we expect Exchange to have a favorable impact of approximately 1% on full year reported sales. For the second quarter, we expect Exchange to have relatively neutral impact on sales. And for the second quarter, we forecast adjusted earnings per share of $1.25 to $1.31. With that, we’ll now open the call for questions.
OPERATOR
Thank you. At this time we will conduct the question and answer session. As a reminder to ask a question, you will need to press star 11 on your telephone. You will then hear an automated message advising you that your hand is raised to withdraw your question. Please press star 11 again. For optimal sound quality, we kindly ask that you use your handset instead of your speakerphone when asking your question. Again, that’s star 11 to ask a question. And please stand by. We compile our Q and A roster. And our first question will come from David Roman from Goldman Sachs. Your line is open.
David Roman (Equity Analyst at Goldman Sachs)
Thank you and good morning everyone. Thanks for taking the question. Maybe I’ll start with just the updated guidance. And I know you touched on some of this during the call, but maybe you could just go into some further detail on firstly maybe your guidance philosophy and your thought process in establishing the revised outlook. And then secondly, just the extent to which the outlook is in your mind sort of fully de risks and captures upside potential, but also contemplates any downside, unforeseen risks here.
Robert Ford (Chairman and Chief Executive Officer)
Yeah, sure. I mean, I think the philosophy here, David, is, I think maybe there’s a portion there that is, you know, we’ve included exact sciences into the history and our philosophy there has always been to ensure that our investors have, you know, clear, transparent, detailed kind of breakdown of our performance. We did that during COVID if you remember, we always split out the COVID sales and we got feedback that they really wanted to understand the underlying part of the business and the COVID part of the business. When we did the acquisition of St. Jude, the acquisition closed in the first quarter and so we did the same approach there to fold in St. Jude into a kind of more comparable basis. And we just think it provides the investors really the most relevant growth rate, a growth rate that is, of the new Abbott portfolio on a very kind of clean, apples to apples basis. So I think that’s the philosophy there as it relates to the guidance. I think maybe the view there was just maybe a little bit of a take a little bit of a conservative side here on some aspects that we felt in the first quarter. For example, if you look at the respiratory season, we forecasted Q1 to be a relatively weak season compared to other seasons that we had seen in the past. And then that was even weaker than what we had forecasted. And I think as we’ve looked at other comparable healthcare businesses that we look at, for example, OTC meds, which is a very good kind of triangulation there, we’re seeing also those types of businesses have this year over year effect there. One of the ways to think about it is like, okay, you have two parts in the year where you’re going to have this effect. You have it at the beginning of the year and you have it at the end of the year. So one of the ways to think about it is, okay, we’re going to make that lower respiratory season at the back end of the year and then we would have to assume that you would have an above average respiratory season, at least from a testing perspective. But I’m only going to find that out just before Thanksgiving. So I just thought it was prudent to say, you know what, we’re not going to be able to make up, or I’ll put it this way, I’m not going to forecast that we’re going to make it up in Q4. This respiratory aspect. That doesn’t mean we won’t be ready. Obviously, you know our portfolio and we know we’ve got the manufacturing, the capabilities and the distribution to be able to do that. I just decided that I didn’t think it was prudent to bake that into the forecast. The rest of the, you know, the rest of the areas of the business, the sales growth out is very much in line with our January, with our January outlook. And if I go back to the way I described our year and the year progression, there’s a couple key kind of blocks that really drive our growth throughout the year. I’d say the first block here is, just as I said in my comments, sustaining the growth of our medtech business and our pharma business. Medtech business low double digits, our pharma business above 7%. These are businesses that have consistently and reliably deliver this type of performance. And whether it’s market conditions or new product launches in these businesses, we feel very good about our ability to be able to sustain that kind of performance. The other bucket, I would say the second bucket would probably be more okay, Trajectory changing businesses. And I would put diagnostics, especially our core lab business and nutrition into those buckets. I think they’re a little bit different though, David, I would say on our core lab business and we talked about this last year, the impacts of China and the VBP and obviously Covid, that was about a billion dollar headwind that we faced last year. Other parts of the business geography, other parts of the platforms doing very well, growth, and we continue to see that. So what I’ve seen over the last six months really gives me confidence that we’re actually on very much either on track or slightly ahead of that recovery in our diagnostics and that growth trajectory change. And I think the teams there have done an incredible job in China and especially here in the US Too. I think the teams have done really good in terms of being able to capture market share. The nutrition transition I think is a little bit earlier on in that stage. But I still feel that what we’re seeing right now, the decisions that we took, the timely …
This post was originally published here
